Vimarsana
Biggest News Aggregation in the World

Page 27 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

AstraZeneca : ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience - Vimarsana News

AstraZeneca : ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience

AstraZeneca : ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience 05/19/2021 | 05:06pm EDT Send by mail : Message : Required fields LYNPARZA is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer CALQUENCE shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib IMFINZI five-year data represent longest-ever...

Imfinzi, tremelimumab combo boosts survival in lung cancer - Vimarsana News

Imfinzi, tremelimumab combo boosts survival in lung cancer

Imfinzi, tremelimumab combo boosts survival in lung cancer 7th May 2021 A combination of AstraZeneca's Imfinzi (durvalumab), tremelimumab and chemotherapy has extended overall survival (OS) when used as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). A final analysis of data from the POSEIDON study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone. The trial also tested a combination of Imfinzi plus chemotherapy which, while showing a statistically significant improvement in progression-...

Top UK Stocks to Watch: IHG expects recovery to gain momentum - Vimarsana News

Top UK Stocks to Watch: IHG expects recovery to gain momentum

Top UK Stocks to Watch: IHG expects recovery to gain momentum Joshua Warner May 7, 2021 9:01 AM IHG hopes to be on the road to recovery, IAG calls for governments to do more to let international travel resume, St Modwen shares jump following a takeover offer, AstraZeneca sees positive results from its lung cancer trial, and three companies prepare to IPO in London. Share: Top News: IHG sees pick-up in demand in Americas and China InterContinental Hotel...

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Imfinzi + tremelimumab showed survival in POSEIDON - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Imfinzi + tremelimumab showed survival in POSEIDON

  Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage IV non-small cell lung cancer     but a trend in overall survival did not achieve statistical significance   POSEIDON was a Phase III trial of AstraZeneca's Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).   Positive high-level r...

Tagrisso moves closer towards EU approval for early-stage lung cancer - Vimarsana News

Tagrisso moves closer towards EU approval for early-stage lung cancer

Tagrisso moves closer towards EU approval for early-stage lung cancer 27th April 2021 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s (AZ) Tagrisso for approval in the EU for the treatment of early-stage lung cancer patients. Specifically, the CHMP has recommended a marketing authorisation for Tagrisso (osimertinib) for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection. The positive opinion is ...